$SBC

Emerging Growth Research released an updated quarterly report on SBC Medical Group Holdings Inc. (NASDAQ:SBC), highlighting 13% YoY revenue growth to $49.2M in Q2:26, improved profitability, AI-driven initiatives, and global expansion. The company reported $185M in cash and $38M in debt, with a Debt/Book Equity ratio of 14%.

SBC Medical Group reported a 32% EBITDA surge in Q2, with Gorilla Clinic's transaction value up 19% YoY to $62M. The company is expanding non-aesthetic healthcare, using AI for efficiency, and pursuing M&A. It expects $15M in annual service-fee increases. SBC is also advancing U.S. and Southeast Asia expansion, with plans for a longevity center in Japan. The company has $184M in cash for growth and M&A, aiming for steady EPS growth.

SBC Medical Group Holdings (NASDAQ: SBC) reported Q2FY26 revenue of $49.2M, up 13% YoY, and operating profit growth of 30%. The company attributed the growth to franchise fee normalization and the inclusion of Waqoo operations. SBC has $185M in cash and $38M in debt, with plans for AI integration and global expansion.

Emerging Growth Research released an updated Q2:26 report on SBC Medical Group Holdings Inc. (NASDAQ:SBC), highlighting 13% revenue growth to $49.2M, 30% operating profit increase, AI-driven initiatives, and global expansion. SBC has $185M in cash and $38M in debt. The report is company-sponsored, with EGR disclosing a $25,000 payment from SBC.

SBC Medical Group Holdings (NASDAQ:SBC) reported Q2:26 revenue of $49.2M, up 13% YoY, with operating profit rising 30% YoY. EGR expects AI clinic initiatives to add up to $15M in H2:26 revenue. The company has 287 clinics in Japan and is expanding globally. SBC had $185M in cash and $38M in debt, with a Debt/Book Equity ratio of 14%.

Emerging Growth Research reiterated a Buy rating on SBC Medical Group (NASDAQ: SBC) and raised its price target to $11.00. Q2:26 revenue grew 13% YoY to $49.2M, with net income rising to $10.7M. The company expects AI initiatives to add up to $15M in annual revenue and expanded its clinic network by 34 locations. SBC ended Q2:26 with $147M in net cash.

SBC Medical Group (NASDAQ:SBC) reported Q2 earnings call highlights. Management said customer numbers and spending per customer are rising, with aesthetic dermatology growing faster than the market. First-half transaction value increased 19% YoY. SBC plans multi-brand clinic expansion, AI-driven cost and growth initiatives, and targets 1,000 clinics by 2035. It expects JPY 15m full-year annual revenue from call-center and support changes.

SBC Medical Group Holdings (Nasdaq: SBC) reported Q2 FY2026 results for the three months ended June 30, 2026. Total revenue rose 13% to $49 million. Net income attributable to SBC Medical increased 335% to $11 million, and Adjusted EBITDA rose 32% to $20 million. The company cited AI-enabled fee increases and expects about $15 million in annual service-fee gains if fully realized.

SBC Medical Group Holdings Inc (SBC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SBC Medical Group Holdings Reports Second Quarter 2026 Financial Results Restructuring Complete, Growth Reaccelerates: Q2 Revenue Up 13%, Net Income Attributable to SBC Medical Up 335%, Adjusted EBITDA 1 Up 32% Year-over-Year. AI-Enabled Service Enhancements Drive Su

SBC Medical Group Holdings Inc (SBC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. EX-3.2 3 ex3-2.htm EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF SBC MEDICAL GROUP HOLDINGS INCORPORATED Adopted: July 8, 2026 1. Offices . The address of the registered office of SBC Medical Group Holdings Incorporated (the “ Corporation ”) in the State of Delaware, and the